Skip to main content
Figure 8 | Respiratory Research

Figure 8

From: Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study

Figure 8

Mean changes from baseline to week 24 in (A) E-RS overall average daily score over the study period, (B) nighttime symptom severity, and (C) early morning symptom severity. Parenthetical values are the percent changes from baseline for the specified group. The E-RS analysis was conducted using the ITT exacerbation population, defined as all randomized patients who received ≥1 dose of double-blind study drug; the analyses of nighttime and early morning symptom severity were conducted using the general ITT population. For all outcomes, mean changes were analyzed using a mixed-model for repeated measures. *p< 0.05 versus placebo; †p< 0.05 versus aclidinium and placebo; §p< 0.05 versus aclidinium, formoterol, and placebo. ACL400/FOR12 FDC, fixed-dose combination of aclidinium 400μg and formoterol 12μg; ACL400/FOR6 FDC, fixed-dose combination of aclidinium 400μg and formoterol 6μg; EMSCI, early morning symptoms of COPD instrument; E-RS, EXACT respiratory symptoms; ITT, intention-to-treat; LS, least square; NiSCI, nighttime symptoms of COPD instrument.

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us